The Biomarkers Consortium Completes First Project to Show that Adiponectin is a Predictive Biomarker for Type 2 Diabetes
BETHESDA, Md.--(BUSINESS WIRE)--Jun 25, 2009 - The use of adiponectin, a hormone derived from fat cells, was confirmed as a robust biomarker predictive of glycemic efficacy in Type 2 diabetes and healthy subjects, after treatment with peroxisome proliferator-activated receptor-agonists (PPAR), but not after treatment with non-PPAR drugs such as metformin. The findings were the result of the first project completed by the Biomarkers Consortium, a public-private partnership managed by the Foundation for the National Institutes of Health. The project conducted a statistical analysis of pooled and blinded pre-existing data from Phase II clinical trials contributed by four pharmaceutical companies and analyzed under the direction of a diverse team of scientists from industry, the National Institutes of Health (NIH), U.S. Food & Drug Administration (FDA), and academic research institutions.
Type 2 diabetes accounts for more than 90% of all diabetes. It is estimated to reach 330 million cases by 2030. The results suggest that adiponectin can predict glycemic response in as little as six weeks and across the spectrum of glucose tolerance.
The project pooled blinded data from existing completed clinical trials contributed by Eli Lilly and Company, GlaxoSmithKline, Hoffmann-LaRoche, Inc, and Merck Research Laboratories into a single database hosted by Quintiles Transnational Corporation. Two separate statisticians analyzed the data. The results were recently presented at the 69th Scientific Session of the American Diabetes Association this June and have just been published in Clinical Pharmacology and Therapeutics Online at http://www.nature.com/doifinder/10.1038/clpt.2009.88.
For full release, go to www.fnih.org.
Contact: Foundation for the National Institutes of Health
Thuy Morzenti, 301-594-9928
